Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8979830 | 0.90 | LTB4R2 (0.46) | AGTR1AGTR2LTB4R2ACHEBDKRB1 | |
| SCHEMBL9199769 | 0.90 | CNR1 (0.39) | AGTR1AGTR2 | |
| SCHEMBL9195058 | 0.81 | LTB4R2 (0.40) | AGTR1AGTR2LTB4R2ACHE | |
| SCHEMBL8979911 | 0.80 | AGTR1 (0.46) | AGTR1AGTR2LTB4R2ACHE | |
| SCHEMBL9538974 | 0.79 | ACHE (0.49) | AGTR1AGTR2ACHE | |
| SCHEMBL9286819 | 0.79 | AGTR1 (0.47) | AGTR1AGTR2LTB4R2ACHE | |
| SCHEMBL8979766 | 0.78 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL8979783 | 0.77 | AGTR1 (0.48) | AGTR1AGTR2LTB4R2ACHEBDKRB1 | |
| SCHEMBL8979770 | 0.77 | AGTR1 (0.56) | AGTR1AGTR2 | |
| SCHEMBL8979743 | 0.76 | AGTR1 (0.52) | AGTR1AGTR2LTB4R2ACHEBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5565464-A | Compounds having angiotensine II antagonistic activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1996-10-15 | — | — | US | disclosed |
| WO-1993003018-A1 | COMPOUNDS HAVING ANGIOTENSINE II ANTAGONISTIC ACTIVITY | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1993-02-18 | — | — | WO | disclosed |